Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study—IMEA 055
Antoine Bachelard(Lyon 1 Université), Fatima Touam(Hôpital Necker-Enfants Malades), Thomas Gabas, Marion Mora(Inserm), Claudine Duvivier(Hôpital Necker-Enfants Malades), Ophélia Godin(Inserm), Valentina Isernia(Hospital Clínico San Carlos), Cécile Donadille(Inserm), Martin Siguier, Sabrinel Sahali(Lyon 1 Université), Diane Descamps(Université Claude Bernard Lyon 1), Marc‐Antoine Valantin, André Cabie, Lise Cuzin, Gilles Peytavin(Université Claude Bernard Lyon 1), Laurence Fagour, Bruno Spire(Inserm), Karine Lacombe(Inserm), G. Pialoux, Sylvie Abel(Hospital for Tropical Diseases), Amina Fadli, Marie Préau(Inserm), Erwan Fourn(Inserm), Lambert Assoumou(Inserm), Christia Palacios, Ornella Cabras, Mayssam El Mouhebb(Inserm), Julie Chas(Inserm), Charlotte Charpentier(Lyon 1 Université), Roland Landman, Sandrine Pierre-François(Centre Hospitalier Universitaire de Martinique), Aı̈da Benalychérif(Lyon 1 Université), Amélie Chabrol, Éric Farfour(European Foundation for Clinical Nanomedicine), Elisabete Gomes Pires, Nouara Agher, Cathia Soulié(Inserm), David Zucman(Hôpital Foch)
Cited by 14
Related Papers
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
|The Lancet Respiratory Medicine|2021|297